Moderna (MRNA) Competitors

argenx (NASDAQ:ARGX) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.

Do insiders and institutionals have more ownership in ARGX or MRNA?

60.3% of argenx shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 2.4% of argenx shares are held by company insiders. Comparatively, 11.0% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in ARGX or MRNA?

argenx received 442 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 67.38% of users gave argenx an outperform vote while only 53.62% of users gave Moderna an outperform vote.

Company	Underperform	Outperform
argenx	Outperform Votes 657 67.38%	Underperform Votes 318 32.62%
Moderna	Outperform Votes 215 53.62%	Underperform Votes 186 46.38%

Do analysts rate ARGX or MRNA?

argenx currently has a consensus target price of $699.28, suggesting a potential upside of 8.39%. Moderna has a consensus target price of $58.70, suggesting a potential upside of 105.68%. Given Moderna's higher possible upside, analysts clearly believe Moderna is more favorable than argenx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenx	0 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91
Moderna	4 Sell rating(s)	16 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04

Which has better earnings and valuation, ARGX or MRNA?

argenx has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenx	$2.19B	17.99	-$295.05M	$12.59	51.24
Moderna	$3.20B	3.45	-$3.56B	-$9.28	-3.08

Does the media favor ARGX or MRNA?

In the previous week, Moderna had 11 more articles in the media than argenx. MarketBeat recorded 32 mentions for Moderna and 21 mentions for argenx. argenx's average media sentiment score of 1.29 beat Moderna's score of 0.98 indicating that argenx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenx	14 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	18 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Positive

Is ARGX or MRNA more profitable?

argenx has a net margin of -2.11% compared to Moderna's net margin of -110.04%. argenx's return on equity of -1.45% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenx	-2.11%	-1.45%	-1.29%
Moderna	-110.04%	-28.74%	-21.83%

Which has more risk and volatility, ARGX or MRNA?

argenx has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Moderna has a beta of 2.23, meaning that its stock price is 123% more volatile than the S&P 500.

Summary

argenx beats Moderna on 11 of the 18 factors compared between the two stocks.